Northeast Indiana Bancorp, Inc. Announces Cash Dividend and Holds Twenty-Second Annual Shareholder Meeting

HUNTINGTON, Ind., April 26, 2017 /PRNewswire/ — Northeast Indiana Bancorp, Inc., (OTCQB: NIDB), the parent company of First Federal Savings Bank, has announced that the Corporation will pay a cash dividend of $0.22 per common share.  The dividend will be payable on May 23, 2017 to shareholders of record on May 9, 2017.

Northeast Indiana Bancorp, Inc. held its twenty-second annual shareholders’ meeting April 25, 2017.  The shareholders selected J. David Carnes and William A. Zimmer as directors of the company for terms to expire in 2020.  

The book value of NIDB’s stock was $28.34 per common share as of March 31, 2017.  The last reported trade of stock at the close of business on April 24, 2017 was $35.00 per common share and the number of outstanding shares was 1,214,879 as of the same date.  The annualized dividend yield is currently 2.5% when annualizing the current quarter cash dividend of $0.22 per common share against the April 24, 2017 closing price of $35.00 per common share. 

Northeast Indiana Bancorp, Inc. is headquartered at 648 N. Jefferson Street, Huntington, Indiana.  The company offers a full array of banking and financial brokerage services to its customers through its main office in Huntington and five full-service Indiana offices in Huntington (2), Warsaw and Fort Wayne (2).  The Company is traded on the OTC Markets Group, Inc. (www.otcmarkets.com) utilizing the OTCQB platform under the symbol „NIDB”.  Our web site address is www.firstfedindiana.bank.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/northeast-indiana-bancorp-inc-announces-cash-dividend-and-holds-twenty-second-annual-shareholder-meeting-300446150.html

SOURCE Northeast Indiana Bancorp, Inc.

Related Links

http://www.firstfedindiana.bank

GVCL Ventures, Inc. Approves Global Vision Cannabis Life as its Operating Name

POMPANO BEACH, Fla., April 26, 2017 /PRNewswire/ — GVCL Ventures, Inc. (the „Company”) (OTC: GVCL) is pleased to announce it has approved the registration of Global Vision Cannabis Life as a, doing business as, name that focuses the company and its intended direction going forward.

The Company has been diligent in seeking out and negotiating new business opportunities and/or alliances that will greatly enhance the value and strategic direction of the Company.  We anticipate the completion of one or more of our corporate objectives related to potential acquisitions, joint ventures and product / technology sourcing and development, which are being diligently pursued.  To that end, we have registered Global Vision Cannabis Life to better reflect our corporate pursuits.

The trading symbol for the Company remains as GVCL and Global Vision Cannabis Life well represents both the formal corporate name and trading symbol. There are no corporate equity changes related to the name registration.  As well, the Company’s website remains as www.gvclventures.com.

Gerald Neziol, President of the Company, states, „We are very excited by the progress we have made in pursuing our current direction and the opportunities that have presented themselves which we anticipate will come to fruition shortly and greatly enhance the Company and its value to its shareholders and clients.”

About GVCL Ventures, Inc.:

GVCL Ventures, Inc. (www.gvclventures.com), doing business as Global Vision Cannabis Life, is a business opportunity company seeking unique companies to work with for the purpose of enhancing shareholder value, in symphony with its wholly owned subsidiary, GVCL Marketing Corp., which provides a unique network marketing opportunity that utilizes its extensive access to online digital campaigns via the internet for its clients and partners, to enhance their productivity and revenue.

Forward Looking Statements
Undue reliance should not be placed on forward looking statements in this press release.  This press release contains forward looking statements that involve risks and uncertainties.  Words such as „will”, „anticipates”, „believes”, „plans”, „goal”, „expects”, „future”, „intends”, and similar expressions are used to identify these forward looking statements.  Actual results could materially differ from those anticipated in these forward looking statements for many reasons.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/gvcl-ventures-inc-approves-global-vision-cannabis-life-as-its-operating-name-300446133.html

SOURCE GVCL Ventures, Inc.

Related Links

http://www.gvclventures.com

Global Floor Coverings Market 2017 Share,Trend,Segmentation and Forecast to 2022

WiseGuyReports.Com Publish a New Market Research Report On – Global Floor Coverings Market 2017 Share,Trend,Segmentation and Forecast to 2022”.

                                                                                                                         

In this report, the global Floor Coverings market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Floor Coverings in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
China
Japan
Southeast Asia
India

 

Get a Sample Report @  https://www.wiseguyreports.com/sample-request/1223757-global-floor-coverings-market-research-report-2017

For more information or any query mail at sales@wiseguyreports.com

 

Global Floor Coverings market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
IKEA
Walmart
Bed Bath & Beyond
Macy’s
Ahold
Aldi
Ashley Furniture
Carrefour
Continental China
Crate & Barrel
Fred Meyer
Furniture Brands International
Future Group
Haworth
Herman Miller
Inditex
Kimball International

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
PVC
Knit
Pearl cotton
other

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Floor Coverings for each application, including
Household
Commercial

If you have any special requirements, please let us know and we will offer you the report as you want.

 

Enquiry About Report @ https://www.wiseguyreports.com/enquiry/1223757-global-floor-coverings-market-research-report-2017

 

Table Of Contents – Major Key Points

 

Global Floor Coverings Market Research Report 2017
1 Floor Coverings Market Overview
1.1 Product Overview and Scope of Floor Coverings
1.2 Floor Coverings Segment by Type (Product Category)
1.2.1 Global Floor Coverings Production and CAGR (%) Comparison by Type (Product Category) (2012-2022)
1.2.2 Global Floor Coverings Production Market Share by Type (Product Category) in 2016
1.2.3 PVC
1.2.4 Knit
1.2.5 Pearl cotton
1.2.6 other
1.3 Global Floor Coverings Segment by Application
1.3.1 Floor Coverings Consumption (Sales) Comparison by Application (2012-2022)
1.3.2 Household
1.3.3 Commercial
1.4 Global Floor Coverings Market by Region (2012-2022)
1.4.1 Global Floor Coverings Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
1.4.2 North America Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 China Status and Prospect (2012-2022)
1.4.5 Japan Status and Prospect (2012-2022)
1.4.6 Southeast Asia Status and Prospect (2012-2022)
1.4.7 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Floor Coverings (2012-2022)
1.5.1 Global Floor Coverings Revenue Status and Outlook (2012-2022)
1.5.2 Global Floor Coverings Capacity, Production Status and Outlook (2012-2022)

2 Global Floor Coverings Market Competition by Manufacturers
2.1 Global Floor Coverings Capacity, Production and Share by Manufacturers (2012-2017)
2.1.1 Global Floor Coverings Capacity and Share by Manufacturers (2012-2017)
2.1.2 Global Floor Coverings Production and Share by Manufacturers (2012-2017)
2.2 Global Floor Coverings Revenue and Share by Manufacturers (2012-2017)
2.3 Global Floor Coverings Average Price by Manufacturers (2012-2017)
2.4 Manufacturers Floor Coverings Manufacturing Base Distribution, Sales Area and Product Type
2.5 Floor Coverings Market Competitive Situation and Trends
2.5.1 Floor Coverings Market Concentration Rate
2.5.2 Floor Coverings Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

………

7 Global Floor Coverings Manufacturers Profiles/Analysis
7.1 IKEA
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Floor Coverings Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 IKEA Floor Coverings Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.1.4 Main Business/Business Overview
7.2 Walmart
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Floor Coverings Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Walmart Floor Coverings Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.2.4 Main Business/Business Overview
7.3 Bed Bath & Beyond
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Floor Coverings Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Bed Bath & Beyond Floor Coverings Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.3.4 Main Business/Business Overview
7.4 Macy’s
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 Floor Coverings Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
7.4.3 Macy’s Floor Coverings Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.4.4 Main Business/Business Overview
7.5 Ahold
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.5.2 Floor Coverings Product Category, Application and Specification
7.5.2.1 Product A
7.5.2.2 Product B
7.5.3 Ahold Floor Coverings Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.5.4 Main Business/Business Overview
7.6 Aldi
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.6.2 Floor Coverings Product Category, Application and Specification
7.6.2.1 Product A
7.6.2.2 Product B
7.6.3 Aldi Floor Coverings Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.6.4 Main Business/Business Overview
7.7 Ashley Furniture
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.7.2 Floor Coverings Product Category, Application and Specification
7.7.2.1 Product A
7.7.2.2 Product B
7.7.3 Ashley Furniture Floor Coverings Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.7.4 Main Business/Business Overview
7.8 Carrefour
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.8.2 Floor Coverings Product Category, Application and Specification
7.8.2.1 Product A
7.8.2.2 Product B
7.8.3 Carrefour Floor Coverings Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.8.4 Main Business/Business Overview
7.9 Continental China
7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.9.2 Floor Coverings Product Category, Application and Specification
7.9.2.1 Product A
7.9.2.2 Product B
7.9.3 Continental China Floor Coverings Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.9.4 Main Business/Business Overview

Continued…….

 

For more information or any query mail at sales@wiseguyreports.com

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1223757

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

ABOUT US:

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of rmaket research reports under these categories and sub-categories.

Global Passenger Boarding Bridge (PBB) Market to reach approximately $1.49 billion by 2025

NEW YORK, April 26, 2017 /PRNewswire/ — This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc. The market data is gathered from extensive primary interviews and secondary research. The market size is calculated based on the revenue generated through sales from all the given segments and sub segments in the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.

This report provides data tables, includes charts and graphs for visual analysis.

Regional Analysis:
North America
– US
Canada
Mexico

Europe
France
Germany
Italy
Spain
– UK
– Rest of Europe

Asia Pacific
China
Japan
India
Australia
New Zealand
– Rest of Asia

Middle East
Saudi Arabia
– UAE
– Rest of Middle East

Latin America
Argentina
Brazil
– Rest of Latin America

Rest of the World
Africa
Caribbean

Report Highlights:
– The report provides a detailed analysis on current and future market trends to identify the investment opportunities
– Market forecasts till 2025, using estimated market values as the base numbers
– Key market trends across the business segments, Regions and Countries
– Key developments and strategies observed in the market
– Market Dynamics such as Drivers, Restraints, Opportunities and other trends
– In-depth company profiles of key players and upcoming prominent players
– Growth prospects among the emerging nations through 2025
– Market opportunities and recommendations for new investments
Read the full report: http://www.reportlinker.com/p04772854/Global-Passenger-Boarding-Bridge-PBB-Market-Analysis-Trends-Industry-Forecast-to.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-passenger-boarding-bridge-pbb-market-to-reach-approximately-149-billion-by-2025-300446167.html

SOURCE Reportlinker

Related Links

http://www.reportlinker.com

Global Personal Protective Equipment Market to reach approximately $74.78 billion by 2025

NEW YORK, April 26, 2017 /PRNewswire/ — The Global Personal Protective Equipment Market is poised to grow at a CAGR of around 7.5% over the next decade to reach approximately $74.78 billion by 2025.

This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc. The market data is gathered from extensive primary interviews and secondary research. The market size is calculated based on the revenue generated through sales from all the given segments and sub segments in the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.

This report provides data tables, includes charts and graphs for visual analysis.

Regional Analysis:
North America
– US
Canada
Mexico

Europe
France
Germany
Italy
Spain
– UK
– Rest of Europe

Asia Pacific
China
Japan
India
Australia
New Zealand
– Rest of Asia

Middle East
Saudi Arabia
– UAE
– Rest of Middle East

Latin America
Argentina
Brazil
– Rest of Latin America

Rest of the World
Africa
Caribbean

Report Highlights:
– The report provides a detailed analysis on current and future market trends to identify the investment opportunities
– Market forecasts till 2025, using estimated market values as the base numbers
– Key market trends across the business segments, Regions and Countries
– Key developments and strategies observed in the market
– Market Dynamics such as Drivers, Restraints, Opportunities and other trends
– In-depth company profiles of key players and upcoming prominent players
– Growth prospects among the emerging nations through 2025
– Market opportunities and recommendations for new investments
Read the full report: http://www.reportlinker.com/p04772855/Global-Personal-Protective-Equipment-Market-Analysis-Trends-Industry-Forecast-to.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-personal-protective-equipment-market-to-reach-approximately-7478-billion-by-2025-300446173.html

SOURCE Reportlinker

Related Links

http://www.reportlinker.com

JLL Income Property Trust Announces Q1 2017 Portfolio Activities

CHICAGO, April 26, 2017 /PRNewswire/ — 

JLL Income Property Trust, an institutionally managed daily NAV REIT (NASDAQ: ZIPTAX; ZIPTMX; ZIPIAX; ZIPIMX) today announced the results of its execution on a number of strategic initiatives in the first quarter of 2017, which helped drive operational and investment performance while positioning the company for future growth and enhanced stockholder value.

JLL Income Property Trust ended the first quarter with $2.3 billion in total assets made up of a geographically diversified portfolio of 69 core properties spanning the retail, apartment, industrial and office property sectors. The portfolio is highly leased with an overall occupancy of 95 percent, and an average remaining lease term of 6.3 years, supporting JLL Income Property Trust’s investment objectives of generating attractive income for distribution to stockholders. As a testament to the quality of the portfolio, leasing activity remained robust, with a total of 36,000 square feet of new leases and renewals completed during the quarter.

„Investment performance is the most important measure of success, and our sustained focus on active asset management, portfolio diversification and leverage reduction has driven our positive first quarter results. Real estate fundamentals remain strong into the second quarter, as higher occupancies continue to support rent growth across our portfolio,” said Allan Swaringen, President and CEO of JLL Income Property Trust.

JLL Income Property Trust is an institutionally managed, daily NAV REIT that gives investors access to a growing portfolio of commercial real estate investments selected by an institutional investment management team and sponsored by one of the world’s leading real estate services firms.

For more information on JLL Income Property Trust, please visit our website at www.jllipt.com.

About JLL Income Property Trust (NASDAQ: ZIPTAX; ZIPTMX; ZIPIAX; ZIPIMX), Jones Lang LaSalle Income Property Trust, Inc. is a daily NAV REIT that owns and manages a diversified portfolio of high quality, income-producing office, retail, industrial and apartment properties located primarily in the United States. JLL Income Property Trust expects to further diversify its real estate portfolio over time, including on a global basis. For more information, visit www.jllipt.com.

About LaSalle Investment Management
LaSalle Investment Management, Inc., a member of the JLL group and advisor to JLL Income Property Trust, is one of the world’s leading global real estate investment managers with nearly 700 employees in 17 countries worldwide and approximately $60 billion of assets under management of private and public property equity and debt investments. LaSalle’s diverse client base includes public and private pension funds, insurance companies, governments, endowments and private individuals from across the globe. For more information, visit www.lasalle.com.

Forward Looking Statements/Past Performance
This press release may contain forward-looking statements with respect to JLL Income Property Trust. Forward-looking statements are statements that are not descriptions of historical facts and include statements regarding management’s intentions, beliefs, expectations, plans or predictions of the future. Because such statements include risks, uncertainties and contingencies, actual results may differ materially from those expressed or implied by such forward-looking statements. In addition, past performance does not guarantee future results. 

SOURCE JLL Income Property Trust

Global Biomarker Partnering Terms and Agreements 2010-2017: Deal trends, players and financials

NEW YORK, April 26, 2017 /PRNewswire/ — Summary
The Global Biomarker Partnering Terms and Agreements 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies

Read the full report: http://www.reportlinker.com/p03679174/Global-Biomarker-Partnering-Terms-and-Agreements-Deal-trends-players-and-financials.html

Description
The Global Biomarker Partnering Terms and Agreements 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

– Trends in biomarker partnering deals
– Biomarker partnering agreement structure
– Biomarker partnering contract documents
– Top biomarker deals by value
– Most active biomarker dealmakers

The Global Biomarker Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Biomarker agreements announced in the healthcare sectors.

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.

The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the biomarker partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 1,000 online deals records of actual biomarker deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Biomarker partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual Biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of Biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biomarker dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Biomarker deals since 2010. Deals are listed by headline value, signed by big pharma, most active Biomarker dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biomarker dealmaking with a brief summary followed by a comprehensive listing of Biomarker deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Biomarker partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Biomarker partnering deals signed and announced since Jan 2010. The chapter is organized by specific Biomarker technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Biomarker partnering company A-Z, deal type definitions and Biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Biomarker partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biomarker technologies and products.

Key benefits

Global Biomarker Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:
– In-depth understanding of biomarker deal trends since 2010
– Access to headline, upfront, milestone and royalty data
– Analysis of the structure of biomarker agreements with numerous real life case studies
– Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies
– Access to most active biomarker dealmakers since 2010
– Insight into the terms included in a biomarker agreement, together with real world clause examples
– Understand the key deal terms companies have agreed in previous deals
– Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope
Global Biomarker Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Biomarker Partnering Terms and Agreements includes:
– Trends in biomarker dealmaking in the biopharma industry since 2010
– Analysis of biomarker deal structure
– Access to headline, upfront, milestone and royalty data
– Case studies of real-life biomarker deals
– Access to biomarker contract documents
– The leading biomarker deals by value since 2010
– Most active biomarker dealmakers since 2010
– The leading biomarker partnering resources

In Global Biomarker Partnering 2010-2017: Deal trends, players, financials and forecasts, the available contracts are listed by:
– Company A-Z
– Headline value
– Stage of development at signing
– Deal component type
– Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Biomarker Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,000 biomarker deals.

Analyzing actual contract agreements allows assessment of the following:
– What are the precise biomarker rights granted or optioned?
– What is actually granted by the agreement to the partner company?
– What exclusivity is granted?
– What is the payment structure for the deal?
– How aresalesand payments audited?
– What is the deal term?
– How are the key terms of the agreement defined?
– How are IPRs handled and owned?
– Who is responsible for commercialization?
– Who is responsible for development, supply, and manufacture?
– How is confidentiality and publication managed?
– How are disputes to be resolved?
– Under what conditions can the deal be terminated?
– What happens when there is a change of ownership?
– What sublicensing and subcontracting provisions have been agreed?
– Which boilerplate clauses does the company insist upon?
– Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
– Which jurisdiction does the company insist upon for agreement law?

Global Biomarker Partnering 2010-2017 provides the reader with the following key benefits:
– In-depth understanding of biomarker deal trends since 2010
– Analysis of the structure of biomarker agreements with numerous real life case studies
– Comprehensive access to over 1,000 actual biomarker deals entered into by the world’s biopharma companies, together with real world clause examples
– Access to headline, upfront, milestone and royalty data
– Full listing of biomarker deals by company A-Z, deal value, phase of development, deal type, and therapy focus
– Identify leading biomarker deals by value since 2010
– Identify the most active biomarker dealmakers since 2010
– Detailed access to actual biomarker deals and contracts enter into by the leading fifty big pharma companies
– Understand the key deal terms companies have agreed in previous deals
Read the full report: http://www.reportlinker.com/p03679174/Global-Biomarker-Partnering-Terms-and-Agreements-Deal-trends-players-and-financials.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-biomarker-partnering-terms-and-agreements-2010-2017-deal-trends-players-and-financials-300446175.html

SOURCE Reportlinker

Related Links

http://www.reportlinker.com

Release of the Original Video „INORI -PRAYER-„! Using the World’s Fastest Projection Technology to Track AyaBambi’s Intense Performance

TOKYO, April 26, 2017 /PRNewswire/ — Creative Production TOKYO (hereafter: TOKYO) released a video, „INORI -PRAYER-” featuring world-famous dance duo AyaBambi. This project was started when Nobumichi Asai (creative director of WOW http://www.w0w.co.jp/) approached collaborators Eiji Tanigawa (film director of TOKYO http://www.lab.tokyo.jp/), the dancing duo AyaBambi, and the Ishikawa Watanabe Laboratory at the University of Tokyo. Using the new high-speed projection technology developed by the Ishikawa Watanabe Laboratory of The University of Tokyo, they set out to create a new, high quality production to present to the world.

  • Details of the New High-Speed Projector „DynaFlash”

DynaFlash (*1) is a new technology developed by the Ishikawa Watanabe Laboratory of The University of Tokyo.This state-of-the-art projector allows for filming at 1000 fps (1000 frames filmed every second), making it one of the fastest in the world. Combined with high-speed sensing technology, 3D mapping technology with highly precise depth measurement, and ultra high-speed 2D tracking technology with a delay of 10ms or less, the team created a mapping system that was able to track a highly intense performance that would have been impossible otherwise (*2).

Global Platinum Group Metals Market 2017-2021 With Anglo American Platinum, Impala Platinum, JSC MMC Norilsk Nickel, Lonmin and Stillwater Mining Dominating – Research and Markets

The global platinum group metals market to grow at a CAGR of 3.09% during the period 2017-2021.

Global Platinum Group Metals Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of platinum group metals.

According to the report, one of the major drivers for this market is increasing use of PGMs in automobiles. PGMs are widely used in autocatalysts that reduce the emission of various hazardous gases such as CO2 and NO2 from vehicles. In addition, these metals are also used in other automobile components such as antilock braking systems, air bag initiators, and spark plugs.

The latest trend gaining momentum in the market is advances in technology. PGMs play a significant role in many technological innovations in many markets in recent years. These metals are used in the production of glass fiber for fiber optic cables, which helps in advanced telecommunication. PGMs are widely used in implants and tools in the medicine. They are also being considered a treatment option for cancer, and platinum is used as an active ingredient in chemotherapy drugs and also in the treatment of Parkinson’s disease.

Further, the report states that one of the major factors hindering the growth of this market is volatility in prices. Metal prices are subject to fluctuation. Since South Africa is the major revenue contributor to the global PGM market, the rand to US dollar exchange plays an important role in this market’s dynamics. A rise in the value of the rand will affect operating and production costs, thereby reducing the profit margins of the vendors.

Key vendors

  • Anglo American Platinum
  • Impala Platinum
  • JSC MMC Norilsk Nickel
  • Lonmin
  • Stillwater Mining

Other prominent vendors

  • North American Palladium
  • African Rainbow Minerals
  • Eastern Platinum
  • Glencore Xstrata
  • Aquarius Platinum
  • Johnson Matthey

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Market segmentation by metal

Part 07: Market segmentation by application

Part 08: Geographic segmentation

Part 09: Decision framework

Part 10: Drivers and challenges

Part 11: Market trends

Part 12: Vendor landscape

Part 13: Key vendor analysis

Part 14: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/8hwxtw/global_platinum

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-platinum-group-metals-market-2017-2021-with-anglo-american-platinum-impala-platinum-jsc-mmc-norilsk-nickel-lonmin-and-stillwater-mining-dominating—research-and-markets-300445857.html

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017

NEW YORK, April 26, 2017 /PRNewswire/ — Summary
The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies

Read the full report: http://www.reportlinker.com/p03812942/Global-Discovery-Stage-Partnering-Terms-and-Agreements-in-Pharma-and-Biotech.html

Description
The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 report.

The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest discovery agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all discovery stage partnering deals announced since 2010 including financial terms where available including over 3,000 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.

Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in discovery stage deals.

Chapter 5 provides a review of discovery stage deal making since 2010. Deals activity is reviewed by year, therapeutic area, technology type, as well as most active dealmakers.

Chapter 6 provides a detailed analysis of discovery stage payment terms including headline, upfront, milestone and royalty rates.

Chapter 7 provides a review of the leading discovery stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 8 provides a comprehensive listing of the top 50 most active discovery stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2010, where a contract document is available in the public domain.

Chapter 10 provides a comprehensive directory of discovery stage partnering deals since 2010.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2010.

In addition, a comprehensive appendix of all discovery deals since 2010 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.

Key benefits

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 provide the reader with the following key benefits:
– In-depth understanding of discovery stage deal trends since 2010
– Access to headline, upfront, milestone and royalty data
– Analysis of the structure of discovery stage agreements with numerous real life case studies
– Insight into the terms included in a discovery stage agreement, together with real world clause examples
– Understand the key deal terms companies have agreed in previous deals
– Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope
Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 is intended to provide the reader with an in-depth understanding and access to discovery stage deal trends and structure of deals entered into by leading companies worldwide.

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 include:
– Trends in discovery stage dealmaking in the biopharma industry since 2010
– Analysis of discovery stage deal structure
– Access to headline, upfront, milestone and royalty data
– Case studies of real-life discovery stage deals
– Access to over 3,000 discovery stage deals
– The leading discovery stage deals by value since 2010
– Most active discovery stage dealmakers since 2010
– The leading discovery stage partnering 2010

In Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017, the available contracts are listed by:
– Company A-Z
– Headline value
– Stage of development at signing
– Deal type
– Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 report provides comprehensive access to available deals and contract documents for over 3,000 discovery stage deals.

Analyzing actual contract agreements allows assessment of the following:
– What are the precise rights granted or optioned?
– What is actually granted by the agreement to the partner company?
– What exclusivity is granted?
– What is the payment structure for the deal?
– How aresalesand payments audited?
– What is the deal term?
– How are the key terms of the agreement defined?
– How are IPRs handled and owned?
– Who is responsible for commercialization?
– Who is responsible for development, supply, and manufacture?
– How is confidentiality and publication managed?
– How are disputes to be resolved?
– Under what conditions can the deal be terminated?
– What happens when there is a change of ownership?
– What sublicensing and subcontracting provisions have been agreed?
– Which boilerplate clauses does the company insist upon?
– Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
– Which jurisdiction does the company insist upon for agreement law?

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 report provides the reader with the following key benefits:
– In-depth understanding of discovery stage deal trends since 2010
– Access to headline, upfront, milestone and royalty data
– Comprehensive access to over 3,000 discovery stage deals together with contract documents if available
– Detailed access to actual discovery stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
– Analysis of the structure of discovery stage agreements with numerous real life case studies
– Identify leading discovery stage deals by value since 2010
– Identify the most active discovery stage dealmakers since 2010
– Full listing of discovery stage deals by company A-Z, phase of development, deal type, therapy and technology focus
– Understand the key deal terms companies have agreed in previous deals
Read the full report: http://www.reportlinker.com/p03812942/Global-Discovery-Stage-Partnering-Terms-and-Agreements-in-Pharma-and-Biotech.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-2010–2017-300446178.html

SOURCE Reportlinker

Related Links

http://www.reportlinker.com